Phase II Trial of Allovectin-7® for Head and Neck Cancer

Completed · Phase 3

Conditions studied: Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms, Carcinoma of the Head and Neck

In brief

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Key facts

Study ID

NCT00050388

Run by

Vical

Expected to finish

2002-06-01

Last updated by the study team

2008-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama, Birmingham — Birmingham, Alabama, United States
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Louisiana State University — New Orleans, Louisiana, United States
• University of Michigan Medical Center — Ann Arbor, Michigan, United States
• Henry Ford Health System — Detroit, Michigan, United States
• University Cincinnati Medical Center — Cincinnati, Ohio, United States
• Case Western Reserve University — Cleveland, Ohio, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.